Cancer Organoid

Cholangiocarcinoma Organoid

Cholangiocarcinoma organoids are three-dimensional (3D) models that closely replicate the structure and cellular composition of actual cancer tissue.
By preserving key characteristics of cholangiocarcinoma, including genetic mutations and protein expression patterns, these organoids serve as reliable models for cancer research.
Their ability to maintain tumor heterogeneity and accurately mimic the tumor microenvironment (TME) makes them invaluable for studying disease progression and treatment responses.
As physiologically relevant models, cholangiocarcinoma organoids play a crucial role in advancing precision medicine and facilitating the development of more effective cancer therapies.


Price	1784€+ Login to see price
Organism	Human
Product Type	Tissue derived organoid
Tissue	Bile duct
Disease	Cholangiocarcinoma

Applications

Toxicity

Small molecules

mRNA

Antibody

Cancer vaccine

Immune Cells

Immuno Oncology with TME

Cytotoxic T cell

TIL (Tumor infiltrating lymphocytes)

Regulatory T cell

Macrophage

CAF (Cancer associate fibroblast)

Description

Cellular and structural similarity

Our Cholangiocarcinoma organoids exhibit high pathological similarity to patient-derived tumor tissues, expressing key Cholangiocarcinoma markers such as CK7, CEA and CA19-9.

Immunohistochemistry (IHC) analyses confirm that these markers are expressed in the organoids in patterns consistent with primary tumors, reflecting their differentiation status and histological characteristics.

These pathological marker analyses demonstrate that Cholangiocarcinoma organoids faithfully recapitulate the morphological and molecular features of patient tumors, making them a reliable platform for cancer pathology research, drug development, and personalized therapy evaluation.

Targeted Therapy Development with Mutation-Matched Organoids

The cholangiocarcinoma (CCA) organoid platform provides a physiologically relevant model that reflects the genetic characteristics of patient tumors.

Whole Exome Sequencing (WES) has been performed on the organoid library, identifying key driver mutations commonly found in CCA.

These genomic profiles are visualized using Oncoplots, providing clear interpretation of the genetic features of each organoid model.

With WES data already established, cancer organoids harboring specific gene mutations can be selectively utilized for targeted drug testing, mechanistic studies, and mutation-driven drug response analysis.

CCA organoids serve as versatile models that reflect diverse tumor characteristics such as metastasis, treatment resistance, and drug sensitivity, making them effective for evaluating both standard therapies and novel anticancer strategies.

This platform supports mutation-specific organoid selection and testing, positioning it as a powerful tool for precision oncology and the development of personalized cancer therapies.

Drug sensitivity testing for Precision Oncology

A tailored solution for evaluating the efficacy and resistance of new drugs is available using an established cholangiocarcinoma (CCA) organoid library.

By leveraging comprehensive drug sensitivity data, the most suitable organoid lines are selected based on the characteristics of the investigational drug, enabling precise and reliable drug testing.

Drug sensitivity tests have been conducted using Gemcitabine, Cisplatin, Paclitaxel and 5-FU which are widely used in clinical cancer treatment, and drug response data has been collected from a subset of CCA organoid models, comprising over 10 distinct lines.

This dataset continues to expand as additional testing is performed.

This organoid-based drug sensitivity testing platform enhances the efficiency and reliability of the drug development process and contributes to the advancement of personalized cancer treatment strategies.